Alnylam Pharmaceuticals Short Interest Ratio and Short Volume

Short interest is the volume of Alnylam Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of October 30th, investors have sold 3,590,000 shares of ALNY short. 0.00% of Alnylam Pharmaceuticals' shares are currently sold short. View details.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. Alnylam Pharmaceuticals currently has a short interest ratio of 8.0.

Alnylam Pharmaceuticals saw a increase in short interest in October. As of October 30th, there was short interest totaling 3,590,000 shares, an increase of 5.9% from the previous total of 3,390,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.00% of Alnylam Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sub-industry of "biotechnology" compare to Alnylam Pharmaceuticals: Amgen Inc. (1.22%), Gilead Sciences, Inc. (1.82%), Vertex Pharmaceuticals Incorporated (0.00%), Regeneron Pharmaceuticals, Inc. (2.13%), Biogen Inc. (2.47%), Seagen Inc. (0.00%), Alexion Pharmaceuticals, Inc. (1.94%), Exact Sciences Co. (0.00%), Incyte Co. (0.00%), and BioMarin Pharmaceutical Inc. (0.00%).

As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.66 billion), Aon Plc ($3.83 billion), Analog Devices, Inc. ($3.33 billion), ViacomCBS Inc. ($3.13 billion), Snap Inc. ($3.05 billion), The Clorox Company ($2.85 billion), Uber Technologies, Inc. ($2.80 billion), Moderna, Inc. ($2.26 billion), Simon Property Group, Inc. ($2.02 billion), and International Flavors & Fragrances Inc. ($1.96 billion). View all of the most shorted stocks.

Short selling ALNY is an investing strategy that aims to generate trading profit from Alnylam Pharmaceuticals as its price is falling. Alnylam Pharmaceuticals' stock is trading up $4.28 today. To short Alnylam Pharmaceuticals stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Alnylam Pharmaceuticals will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Alnylam Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ALNY, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ALNY, twice per month. The most recent reporting period available is October, 30 2020.